Scientists on Science
Understanding Clinical Trials in Oncology
Donald A. Berry, PhD
Professor, Department of Biostatistics, UT MD Anderson Cancer Center
Donald Berry is professor in the Department of Biostatistics of the University of Texas MD Anderson Cancer Center. He received his doctorate in statistics from Yale University and has held endowed faculty positions at Duke University and MD Anderson. He has designed and supervised the conduct of many innovative clinical trials, including adaptive Bayesian trials, in cancer and other diseases. A principal focus of his research is the use of biomarkers for learning which patients benefit from which therapies, based on genomics and phenotype. In particular, he designed and is a co-PI of I-SPY 2 and GBM-AGILE, Bayesian adaptive platform clinical trials in high-risk early breast cancer and glioblastoma, respectively. He has authored many books on biostatistics and more than 400 peer-reviewed articles. He is a Thomson Reuters Highly Cited Researcher in recognition of ranking among the top 1 percent of most cited researchers in clinical medicine. He has received numerous research grants from the NIH and NSF and is fellow of the American Statistical Association and of the Institute of Mathematical Statistics. He is founder and co-owner of Berry Consultants, a company that designs innovative clinical trials for industry, cooperative groups, international consortia, and patient advocacy groups.